Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma
The Phase I/II trial conducted by Oslo University Hospital investigates the safety and immunogenicity of a novel mRNA-based dendritic cell vaccine for advanced malignant melanoma. Given the increasing incidence of melanoma and the limited efficacy of current therapies, this approach could address a significant unmet medical need. The competitive landscape includes established immunotherapies such as checkpoint inhibitors and emerging mRNA therapies. Successful outcomes could position this therapy favorably in the melanoma treatment market, which is projected to grow significantly. Diligence should focus on the trial's safety profile, potential for combination therapies, and the regulatory pathway for mRNA-based vaccines.
Indication: Malignant Melanoma
Modality: protein therapy
Target: mRNA-transfected dendritic cells (DCs) targeting tumor-specific antigens in advanced malignant melanoma.
Sponsor: Oslo University Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: mRNA-transfected dendritic cells (DCs) targeting tumor-specific antigens in advanced malignant melanoma.
View original source fields
Condition raw: Malignant Melanoma
Condition normalized: Malignant Melanoma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: mRNA-transfected dendritic cells (DCs) targeting tumor-specific antigens in advanced malignant melanoma.
Target normalized: mRNA-transfected dendritic cells (DCs) targeting tumor-specific antigens in advanced malignant melanoma.